SVRA
NASDAQ HealthcareSavara, Inc. - Common Stock
Biotechnology
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
๐ Market Data
| Price | $5.12 |
|---|---|
| Volume | 1,117,036 |
| Market Cap | 1.05B |
| Beta | 0.310 |
| RSI (14-Day) | 34.6 |
| 200-Day MA | $4.69 |
| 50-Day MA | $5.45 |
| 52-Week High | $7.00 |
| 52-Week Low | $1.89 |
| Forward P/E | -15.71 |
| Price / Book | 6.38 |
๐ฏ Investment Strategy Scores
SVRA scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (70/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Over-Hyped (9/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find SVRA in your text
Paste any article, transcript, or post โ the tool will extract SVRA and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.